证券代码：002365 证券简称：永安药业 公告编号：2025-27 潜江永安药业股份有限公司 潜江永安药业股份有限公司（以下简称"公司"）于 2025年4月28日召开第 七届董事会第六次临时会议，审议通过了《关于提请召开 2024 年年度股东会的 议案》，公司决定于2025年6月24日召开公司2024年年度股东会（以下简称"本 次股东会"），现就有关事宜通知如下： 一、召开会议的基本情况 （一）股东会届次：2024年年度股东会。 （二）股东会召集人：公司董事会。 （三）会议召开的合法、合规性：公司董事会召集、召开本次股东会符合有 关法律法规、深圳证券交易所业务规则和《公司章程》的规定。 关于召开 2024 年年度股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 （四）会议召开的日期、时间： 现场会议召开时间：2025年6月24日（星期二）14:00 网络投票时间：2025年6月24日 1、通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年6月24 日9:15—9:25,9:30-11:30 和13:00—15:00。 2、通过深圳证券 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-22 潜江永安药业股份有限公司 第七届监事会第六次临时会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 潜江永安药业股份有限公司（以下简称"公司"）第七届监事会第六次临时 会议的会议通知于 2025 年 4 月 25 日以书面、电话、传真、电子邮件等形式送达 公司全体监事，会议于 2025 年 4 月 28 日以通讯方式召开，本次会议应参与审议 表决监事 3 人，实际参与审议表决监事 3 人。本次会议的召集和召开符合《公司 法》及《公司章程》的规定。会议以书面记名投票方式表决，通过如下决议： 他股东利益,特别是中小股东利益情形。鉴于交易双方在以往协议期间均能较好 的履行协议规定的义务，同意上述交易。 具体内容详见刊登于中国证监会指定信息披露媒体巨潮资讯网 http://www.cninfo.com.cn 上的《关于与浙江双子智能装备有限公司签订<2025 年度设备制造及系统集成供应框架协议>暨关联交易的公告》。 一、审议通过《关于公司 2025 年第一季度报告的议案》； 表 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-21 潜江永安药业股份有限公司 第七届董事会第六次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第六次临时 会议的会议通知于 2025 年 4 月 25 日以书面、电话、传真、电子邮件等形式送达 公司全体董事，会议于 2025 年 4 月 28 日在公司会议室以通讯方式召开，本次会 议应参与审议表决董事 6 人，实际参与审议表决董事 6 人。本次会议的召集和召 开符合《公司法》及《公司章程》的规定。会议以书面记名投票方式逐项表决， 通过了如下决议： 一、审议通过《关于公司 2025 年第一季度报告的议案》 表决结果：同意 6 票，反对 0 票，弃权 0 票。 公司按照《证券法》、《深圳证券交易所股票上市规则》的相关规定，并根 据自身实际情况，完成了 2025 年第一季度报告的编制和审议工作，公司董事、 监事及高级管理人员就该报告签署了书面确认意见，公司监事会出具了书面审核 意见。 本议案已经公司董事会审计委员会审议通过。 ...

本次公司不分配不转赠。 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 5391.57万股，累计占流通股比： 21.96%，较上期变化： 0.48万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 陈勇 | 1586.70 | 6.46 | 不变 | | 黄冈永安药业（002365）有限公司 | 1052.92 | 4.29 | 不变 | | 中央汇金资产管理有限责任公司 | 761.04 | 3.10 | 不变 | | 李金秀 | 569.06 | 2.32 | 不变 | | 王成华 | 403.05 | 1.64 | 不变 | | 大连市同泽企业管理咨询合伙企业(有限合伙) | 275.90 | 1.12 | 不变 | | 宋颂 | 238.60 | 0.97 | 不变 | | 辽宁望晟电子商务有限公司 | 207.62 | 0.85 | 不变 | | 王建华 | 166.30 | 0.68 | 不变 | | 吴志荣 | 130.38 | 0.53 | 0.48 | 三、分红送配方案情况 一、主要会 ...

Financial Performance - The company's revenue for Q1 2025 was ¥171,153,602.96, a decrease of 12.96% compared to ¥196,644,532.11 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥4,367,181.24, representing a decline of 115.23% from a profit of ¥28,680,093.28 in the previous year[5] - The company's basic earnings per share were -¥0.0151, a decrease of 115.52% from ¥0.0973 in the same period last year[5] - The company reported a net profit of CNY 5,189,100.12, compared to CNY 6,293,983.84 in the previous period, reflecting a decrease of 17.57%[19] - The company reported a net loss of CNY 6,693,941.24, compared to a net profit of CNY 28,476,157.30 in the previous period, indicating a significant decline in profitability[20] - Operating profit decreased to CNY -7,610,730.54 from CNY 34,147,399.94, reflecting a substantial drop in operational performance[20] - The total comprehensive income attributable to the parent company was CNY -4,377,798.76, compared to CNY 26,719,061.16 in the prior period, indicating a significant decline[21] - The company incurred a total profit before tax of CNY -7,790,952.05, compared to CNY 33,833,677.38 in the previous period, highlighting a significant downturn[20] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥24,701,934.36, compared to a negative cash flow of ¥4,904,038.98 in the same period last year, marking a 603.71% improvement[5] - Cash flow from operating activities generated a net inflow of CNY 24,701,934.36, a recovery from a net outflow of CNY -4,904,038.98 in the prior period[21] - The net cash flow from investing activities was -¥108,342,211.78, an increase in outflow of 93.54% compared to -¥55,978,437.10 in the previous year[9] - The company experienced a net cash outflow from investing activities of CNY -108,342,211.78, worsening from a net outflow of CNY -55,978,437.10 in the previous period[22] - Cash and cash equivalents decreased to CNY 211,651,545.97 from CNY 320,405,292.96, a decline of 33.94%[15] - The cash and cash equivalents at the end of the period decreased to CNY 211,651,545.97 from CNY 229,945,727.87, indicating a decline in liquidity[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,255,583,809.39, down 2.30% from ¥2,308,602,905.85 at the end of the previous year[5] - Total assets decreased to CNY 2,255,583,809.39 from CNY 2,308,602,905.85, a reduction of 2.29%[17] - Total liabilities decreased to CNY 235,624,782.19 from CNY 266,545,677.53, a decline of 11.59%[16] - The company’s total equity attributable to shareholders decreased by 0.99% to ¥1,974,121,739.64 from ¥1,993,780,889.08 at the end of the previous year[5] - The company’s total equity decreased to CNY 2,019,959,027.20 from CNY 2,042,057,228.32, a decrease of 1.09%[17] - The company’s short-term borrowings decreased to CNY 29,500,000.00 from CNY 39,526,078.47, a reduction of 25.66%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,971[10] - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63,468,000 shares[10] - The top ten shareholders include both individual and corporate entities, with the largest corporate shareholder being Huanggang Yong'an Pharmaceutical Co., Ltd. at 3.57%[10] - The company has completed a share buyback program, repurchasing 5,537,350 shares, which is 1.88% of the total share capital, with a total expenditure of 40,454,553.49 RMB[11] - The company plans to use the repurchased shares for employee stock ownership plans or equity incentive plans[11] - The maximum buyback price was adjusted to 7.90 RMB per share, effective from July 5, 2024[11] Operational Developments - The company is currently involved in a patent infringement lawsuit, with a favorable ruling received in February 2024, stating no infringement on the claimed patents[12] - The company is actively monitoring the bankruptcy proceedings of the plaintiff in the patent case to protect its interests[12] - The company is in the final stages of expanding its production capacity for taurine food additives to 40,000 tons per year, with an investment of 250 million RMB[13] - A new wholly-owned subsidiary, Fuweile Pet Food (Wuhan) Co., Ltd., has been established with a registered capital of 2 million RMB[14] Expenses - The company’s management expenses decreased by 32.34% to ¥15,216,294.82 from ¥22,488,466.54 in the previous year[8] - Total operating costs increased to CNY 184,150,029.42, up 5.49% from CNY 175,009,541.52 in the previous period[19] - Operating costs included CNY 154,528,544.00 in cost of goods sold, which rose from CNY 140,270,981.04, indicating a 10.16% increase[19] - Research and development expenses were CNY 8,417,652.08, down 16.01% from CNY 10,019,915.12 in the previous period[19] - The company reported a significant increase in financial asset fair value changes, with a loss of ¥2,371,888.97 compared to a gain of ¥3,122,732.45 in the previous year, a change of 175.96%[8]

New Stock Issuance - Tian Gong Co., Ltd. issued shares at a price of 3.94[1] - Ze Run New Energy issued shares at a price of 33.06[1] Rights Issues and Trading Alerts - ST Xin Chao has a tender offer period from April 8, 2025, to May 7, 2025[1] - The second tender offer period for ST Xin Chao is from April 23, 2025, to May 22, 2025[1] - The last trading day for Pu Li Tui is in 14 trading days[1] - The last trading day for Pu Li Zhuang Tui is also in 14 trading days[1] Abnormal Fluctuations - Multiple stocks are flagged for severe abnormal fluctuations, including Dongfang Tong and Ningbo United[1] - A total of 14 stocks are noted for significant price volatility, with specific links to their announcements provided[1] Additional Trading Information - Various stocks have upcoming announcements and trading alerts, including ST Hua Peng and Bei Ding Co., Ltd.[1] - The report includes links to detailed announcements for each stock mentioned, ensuring transparency and accessibility for investors[1]

Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [7] Core Insights - The pharmaceutical sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 1.16% from April 21 to April 25, 2025, outperforming the CSI 300 by 0.78 percentage points [2][12] - Year-to-date, the Shenwan Pharmaceutical Bio Index has decreased by 0.31%, yet it has outperformed the CSI 300 by 3.45 percentage points, ranking 13th among 31 Shenwan first-level industry indices [2][14] - As of April 25, 2025, the valuation of the pharmaceutical sector stands at 26.37 times (TTM overall method, excluding negative values), with a premium of 141.60% compared to the CSI 300 [2][17] Summary by Sections 1. Market Performance Review - The pharmaceutical sector has shown a mixed performance, with notable individual stock movements, including significant gains for companies like Yong'an Pharmaceutical (+31.37%) and Shutaishen (+28.41%), while companies like *ST Jiyuan experienced substantial declines (-43.24%) [3][18] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, among 12 departments, issued the "Special Action Plan to Promote Healthy Consumption," aimed at enhancing the quality of health goods and services to meet the public's needs [4][21] 3. Key Company Announcements - Companies such as Kanghong Pharmaceutical and Yiyue Medical have reported their 2024 annual results, with Kanghong achieving a revenue of 4.453 billion yuan, a year-on-year increase of 12.51%, while Yiyue reported a revenue of 7.566 billion yuan, a decline of 5.09% [22] 4. Industry Perspectives - The report highlights a continued rebound in the pharmaceutical sector, particularly in the innovative drug segment, which is expected to remain a key investment theme for 2025. The focus is shifting from earnings to fundamental changes in the industry and companies as the market enters a performance vacuum period starting in May [5][23][24]

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry [7] Core Insights - The pharmaceutical sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 1.16% from April 21 to April 25, 2025, outperforming the CSI 300 by 0.78 percentage points [2] - Year-to-date, the Shenwan Pharmaceutical Bio Index has decreased by 0.31%, yet it has outperformed the CSI 300 by 3.45 percentage points [2][14] - As of April 25, 2025, the valuation of the pharmaceutical sector stands at 26.37 times (TTM overall method, excluding negative values), with a premium of 141.60% compared to the CSI 300 [17] Summary by Sections 1. Market Performance Review - The pharmaceutical sector has outperformed the CSI 300 index during the specified period, ranking 15th among 31 Shenwan first-level industry indices [12] - The top-performing stocks include Yong'an Pharmaceutical (+31.37%), Shutaishen (+28.41%), and Erkang Pharmaceutical (+27.73%) [3][19] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, among 12 departments, issued the "Special Action Plan for Promoting Healthy Consumption," aimed at enhancing the quality of health goods and services [4][21] 3. Key Company Announcements - Kanghong Pharmaceutical reported a revenue of 4.453 billion yuan for 2024, a year-on-year increase of 12.51%, with a net profit of 1.191 billion yuan, up 14.02% [22] - Yuyue Medical reported a revenue of 7.566 billion yuan for 2024, a year-on-year decrease of 5.09%, with a net profit of 1.806 billion yuan, down 24.63% [22] 4. Industry Perspectives - The pharmaceutical sector continues to rebound, with the innovative drug segment performing particularly well, alongside upstream research reagent sectors [5][23] - The focus is shifting from earnings to industry and company fundamentals as the market enters a performance vacuum period starting in May [5][23] - The report emphasizes the potential of innovative drugs, overseas markets, and the clearing of centralized procurement as key investment themes for 2025 [5][24]

4月10日公司发布的2024年年报数据显示，2024年公司共实现营业总收入8.39亿元，同比下降13.78%， 实现净利润0.62亿元，同比增长601.65%。（数据宝） 近日该股表现 永安药业再度涨停，6个交易日内录得4个涨停，累计涨幅为44.57%，累计换手率为126.44%。截至 9:50，该股今日成交量5677.85万股，成交金额7.08亿元，换手率23.12%。最新A股总市值达38.43亿元， A股流通市值32.02亿元。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%、日换手率达20%上榜龙虎榜2 次，买卖居前营业部中，机构净买入3468.66万元，营业部席位合计净买入6988.25万元。 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.04.25 | -4.28 | 40.91 | -13714.20 | | 2025.04.24 | 10.04 | 20.45 | 5359.70 | | 2025.04.23 | 9.97 | 6.97 | 9161.66 | | 2025.04 ...

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].